MindWalk Holdings Authorizes $2.3 Million Share Buyback Program

MindWalk Holdings Corp. (NASDAQ: HYFT) has received board authorization for a share repurchase program that will allow the bio-native AI company to buy back up to 2.3 million common shares over the next 12 months. The program, which begins October 15, 2025, represents approximately 5% of the company's 46.15 million outstanding shares and signals management's strong belief in MindWalk's future growth prospects.

Chief Executive Officer Jennifer Bath stated that the repurchase initiative demonstrates the company's confidence in its long-term strategic direction and provides flexibility to acquire shares when market prices diverge from intrinsic value. The purchases will be funded through existing cash reserves, investment portfolios, or future operational cash flows, reflecting the company's solid financial position.

MindWalk operates as a bio-native artificial intelligence company focused on transforming drug discovery and development processes. The company's proprietary technology platform combines patented HYFT® technology with the LensAI™ platform to create a unified computational language that integrates sequence, structure, function, and scientific literature data. This integrated approach enables rapid advancement from initial insights to validated drug candidates.

The company's platform supports multiple critical functions in pharmaceutical development, including epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics. By closing the loop between computational analysis and physical validation through its integrated wet lab capabilities, MindWalk aims to accelerate the traditionally lengthy drug discovery timeline. Additional information about the company's technology and operations is available at https://www.ipatherapeutics.com/.

The share repurchase announcement was distributed through AINewsWire, a specialized communications platform focusing on artificial intelligence advancements and innovations. AINewsWire operates as part of the Dynamic Brand Portfolio @IBN, which provides comprehensive corporate communications solutions including wire distribution, media syndication, and social media amplification. The platform's full terms of use and disclaimers can be reviewed at https://www.AINewsWire.com/Disclaimer.

This capital allocation decision comes at a time when biotechnology and AI companies face increasing investor scrutiny regarding cash management and shareholder returns. By implementing a structured buyback program, MindWalk joins a growing number of technology-driven healthcare companies using share repurchases to signal confidence in their business models while potentially enhancing shareholder value through reduced share count and improved earnings per share metrics.